April 22, 2019
August 12, 2020
This is a non-interventional medical chart review study aiming to examine the treatment patterns, effectiveness, and safety of ceftazidime-avibactam in approximately 12 countries (including but not limited to Austria, France, Germany, Greece, Italy, Spain, United Kingdom, Russia, Argentina, Colombia, Brazil, and Mexico), with possible expansion to other countries as ceftazidime-avibactam is launched. Eligible patients are adults who have been treated with ceftazidime-avibactam in routine practice at participating sites since 01 January, 2018 onwards or since the date of launch in the country if it is posterior to 01 January, 2018. As this is an observational study, patients will be treated based on the standard of care at the discretion of their physician. No drugs will be supplied for this study and patients will receive treatment through standard local practice.
This observational study will include approximately 700 hospitalized patients with a gram-negative infection, who have received at least one dose of ceftazidime-avibactam. Patients will be recruited in approximately 62 sites across 12 countries in Europe (including Russia) and Latin America. Patients will be followed from ceftazidime-avibactam initiation until 60 days post hospital discharge, mortality, withdrawal from the study, or loss-to-follow-up, whichever occurs first. Data will be abstracted from medical records using an electronic case report form (eCRF). Baseline data include patient socio-demographics, medical history, and clinical and microbiological characteristics of the infection treated. Follow-up data will include details of treatment over time and clinical, microbiological, and healthcare resource utilization outcomes. Evaluation of clinical success will be performed in patients with at least ≥72 hours of exposure to ceftazidime-avibactam. Safety will be evaluated in all patients exposed to at least one dose of the product.
1. Hospitalized patient ≥18 years old or considered an adult in accordance with the age
of majority in the participant's country of residence at the time of treatment with
2. Patient received ≥1 dose of ceftazidime-avibactam in routine practice at participating
site since 01 January, 2018 onwards or since the date of launch in the country if it
is after 01 January, 2018.
3. Patient underwent microbiologic sampling ≤5 days before the initiation of
ceftazidime-avibactam (irrespective of results and actual bacteriological
4. Patient has all required essential data elements which include:
1. Start and stop dates of ceftazidime-avibactam,
2. Start and stop dates of prior antibiotic therapy used for the index infection,
3. Type of combined antibiotic therapy (if applicable) and start and stop dates of
any antibiotic combined with ceftazidime-avibactam.
5. Evidence of a personally signed and dated informed consent document indicating that
the patient (or a legally acceptable representative) has been informed of all
pertinent aspects of the study where required by local regulations.
Patients must not meet any of the following exclusion criteria to be eligible:
1. The patient is enrolled in any clinical trial of an investigational product. Patients
who are enrolled in non-interventional studies (NISs) (e.g. registries) are eligible
2. The patient has received ceftazidime-avibactam in a compassionate care program
3. The patient was exposed to ceftazidime-avibactam before use for the index infection.
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com
AKH - Medizinische Universität Wien
CHU Angers - Hôpital Hôtel Dieu
University Hospital Jena
Policlinico Universitario Agostino Gemelli
Regional Clinical Hospital #1
SBIH of Moscow City Clinical Hospital # 7
FSBI "State Scientific Centre of Coloproctology" of the MoH of RF
FSBI "Hematological Research Center" MoH of RF
North-West Federal Medical Research Center n.a. V.A. Almazov
SBIH Republican Clinical Hospital n.a. G. G. Kuvatov
Complexo Hospitalario Universitario de Vigo
Hospital Universitari Vall d'Hebron
Hospital Universitari de Bellvitge
Hospital Universitario Reina Sofía
Hopsital Ramón y Cajal
Study Director: Pfizer CT.gov Call Center Pfizer